

PAPER DETAILS

TITLE: Role of red cell distribution width in colorectal cancer diagnosis and prognosis

AUTHORS: Ahmet KARAYIGIT,Dursun Burak ÖZDEMİR,Hayrettin DİZEN,Bülent ÜNAL,İlter
OZER,Murat ULAS

PAGES: 875-881

ORIGINAL PDF URL: <https://dergipark.org.tr/tr/download/article-file/2372137>

Role of red cell distribution width in colorectal cancer diagnosis and prognosis

 Ahmet Karayığit¹,  Dursun Burak Özdemir²,  Hayrettin Dizen³,  Bülent Ünal⁴,  İltir Özer⁵,
 Murat Ulaş⁵

¹University of Health Sciences Adana City Training and Research Hospital, Department of Surgical Oncology, Adana, Turkey

²University of Health Sciences Samsun City Training and Research Hospital, Department of Surgical Oncology, Samsun, Turkey

³Acıbadem Eskişehir Hospital, Department of General Surgery, Eskişehir, Turkey

⁴Istanbul Aydın University Faculty of Medicine, Medical Park Florya Hospital, Department of Organ Transplantation, Istanbul, Turkey

⁵Eskişehir Osmangazi University Faculty of Medicine, Department of Surgical Oncology, Eskişehir, Turkey

Cite this article as: Karayığit A, Özdemir DB, Dizen H, Ünal B, Özer I, Ulaş M. Role of red cell distribution width in colorectal cancer diagnosis and prognosis. J Health Sci Med 2022; 5(3): 875-881.

ABSTRACT

Objective: We aimed to assess whether red cell distribution width (RDW) was associated with pre-operative clinical features or post-operative clinicopathological outcomes in patients with colorectal cancer (CRC), and to determine the utility of RDW as a diagnostic or prognostic marker of CRC.

Material and Method: This retrospective cohort study was conducted between January 2018-May 2021 at a university hospital in Turkey. A total of 188 patients histologically diagnosed with CRC who had undergone surgery were included in the study.

Results: Our study included 118 (62.77%) male patients, and the mean age of the patients was 66.28±11.71 years. We found that RDW values were significantly higher in females compared to males ($p=0.033$), in patients with T3 or T4 tumors compared to those with T1 or T2 tumors ($p<0.001$), in patients with stage 2 and stage 3 tumors compared to stage 1 patients, those with early mortality ($p=0.012$), in patients with right or transverse colon tumors compared to those with descending colon or sigmoid colon or rectum tumors ($p<0.001$), and those that died during follow-up compared to survivors ($p=0.001$). Additionally, age ($r=0.233$, $p<0.001$), tumor size ($r=0.229$, $p=0.002$) and length of stay in hospital ($r=0.167$, $p=0.022$) were positively correlated with RDW values. RDW had 75.7% sensitivity and 67.5% specificity to predict mortality for the cut-off point of 15.7 (AUC: 0.704, 95.0%CI: 0.615-0.793, $p<0.001$).

Conclusion: These results show that RDW has a potential function as a biomarker for the diagnosis and prognosis of CRC.

Keywords: Colorectal cancer, RDW, prognosis, progression, overall survival

INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer worldwide, with more than 1 million new cases and 600.000 deaths annually (1). It is the second leading cause of cancer-related death among both men and women, and leads to increased healthcare expenditure (2).

Although the mechanisms underlying CRC are not fully understood, appropriate screening and accurate prognostic assessment can reduce deaths from CRC. Stool occult blood testing, stool DNA testing, colonoscopy, and computed tomography (CT) have long been used as screening tools in CRC, but these screening tools have many limitations, such as low sensitivity and specificity, invasiveness, and high cost. Thus, simple, inexpensive and readily available biomarkers for the diagnosis and

prognosis of CRC are urgently needed (3). Red blood cell distribution width (RDW) is an important classical element of routine blood examination, mainly reflecting the uniformity of the volume and size of red blood cells. Relatively recent studies have focused on the identification of blood-derived biomarkers that could facilitate the early diagnosis of CRC, but there are currently no widely available markers that can be used to diagnose CRC (4). The RDW value has been shown to be associated with prognosis in various tumors such as renal cell carcinoma, gastric cancer, lung cancer, ovarian cancers, esophageal cancer, endometrial cancer, and breast cancer (3,5). Notably, Ay et al. (6) found that RDW was significantly higher in patients with colon cancer than those with colon

polyps, and that RDW could be used as an early indicator for solid colon tumors. Additionally, two recent studies showed that RDW was associated with cancer stage and survival in patients with CRC (7,8). Taken together, these results suggest that RDW may be useful in the diagnosis and prognosis of CRC (3).

The aim of the present study was to assess whether RDW level was associated with pre-operative clinical features and post-operative clinicopathological outcomes of patients with CRC, and to determine the possible utility of RDW as a diagnostic and/or prognostic parameter in CRC.

MATERIAL AND METHOD

This was a retrospective single center study conducted between January 2018-May 2021 at Department of General Surgery, Eskişehir Osmangazi University. The protocol of this study was approved by the Non-Interventional Clinical Researches Ethics Committee of Eskişehir Osmangazi University (Date:15.06.2021, Decision No: 09), and carried out in accordance with the ethical standards stated in the Declaration of Helsinki and its amendments. As the study has a retrospective nature, the Medical Ethics Committee of the Eskişehir Osmangazi University did not require written informed consent from patients. All samples and information were recorded anonymously.

Study Population and Follow-up

A total of 188 patients histologically diagnosed with CRC who had undergone surgery were included in the study. Other inclusion criteria were: being aged older than 18 and younger than 90 years, having a complete blood count result obtained and studied two weeks before the surgery, and being followed for at least 12 months after surgery. Patients who received neoadjuvant chemotherapy and/or radiotherapy, had an active infection when the blood sample was taken, those in which necessary data were incomplete, patients who were lost to follow-up, subjects with a history of other serious diseases that affect survival outcomes (such as cardiovascular and cerebrovascular diseases, pulmonary diseases, blood diseases, infectious diseases, other malignant tumors, cerebral infarction, pulmonary infarction, uncontrolled hypertension, HIV infection etc.) were excluded from the study.

The following information of each patient was acquired from hospital records: demographic characteristics including age and gender; tumor characteristics including location, size, pathological diagnosis, number of lymph nodes, number of metastatic lymph nodes, differentiation, surgical margin positivity, perineural invasion, lymphovascular invasion, TNM stage and clinical stage (reported according to the pathological classification criteria of the 7th Edition of the American

Joint Committee on Cancer guidelines and the Union International Contre Le Cancer criteria for CRC), liver metastasis. Additionally, surgical characteristics including type and extent of surgery, whether ostomy was opened, laboratory measurements (including complete blood count; CBC) length of stay in hospital, follow-up time; complications including leakage, infection and recurrence, and finally, mortality state (early mortality was defined as death occurring within 30 days of surgery).

Patients were called for check-up at regular intervals for an average of 21 months (0-40) postoperatively, and necessary examinations were performed. All outcomes such as leakage, infection, recurrence and death were recorded.

Laboratory Analysis

Blood samples were acquired from the antecubital vein for the measurement of the CBC before the operation. CBC, including hemoglobin and hematocrit values, white blood cell, neutrophil, lymphocyte, platelet counts, and MPV and RDW values were measured via use of routine devices (Sysmex XE-5000, Japan and Roche, Cobas E601, Switzerland) within 2 weeks prior to the date of surgery.

Pathological Analysis

All of the specimens obtained from fully resected tumors were sent to the pathology unit of the Eskişehir Osmangazi University for pathological examinations. Lymph node metastasis, depth of infiltration and tumor size, pathological type and degree of differentiation, radial surgical margin positivity, distal surgical margin positivity, perineural invasion, and lymphovascular invasion were reported by qualified pathologists.

Statistical Analysis

All study data were entered into an SPSS v25 (SPSS Inc., Chicago, IL, USA) database and analyses were performed. Q-Q plots and histograms were used to assess quantitative variable distributions. Quantitative variables were depicted with mean±standard deviation or median (1st quartile - 3rd quartile) values with regard to normality of distribution (normal and non-normal, respectively), and as frequency (percentage) for categorical data. Between-group comparisons were done with the Mann-Whitney U test or the Kruskal-Wallis test depending on the number of groups being compared, and subsequent post-hoc analyses after Kruskal-Wallis tests were performed with the Bonferroni correction method. Spearman correlation coefficients were calculated to evaluate relationships between quantitative variables. Mortality prediction performance of the RDW was assessed by using Receiver Operating Characteristic (ROC) curve analysis. Optimal cut-off point was determined by using Youden index. Two-tailed p values were calculated and values of $p < 0.05$ were considered to show statistical significance.

RESULTS

Seventy female and 118 male patients were included in our study, and the mean age of the patients was 66.28 ± 11.71 (range 36 - 87) years. Patients and tumor characteristics, laboratory measurements and data obtained throughout clinical follow-up studies are depicted in **Table 1**.

The median RDW value of patients with T3 or T4 tumors was found to be significantly higher than that of patients with T1 or T2 tumors ($p < 0.001$). We also found a significant relationship between RDW and gender (female > male, $p=0.033$), tumor stage (stage 1 values lower than stage 2 and 3 values, $p=0.010$) and mortality. A total of 7 patients had early mortality (postoperative days 0, 2, 3, 5, 14, 22 and 29). The preoperative RDW values of patients who died during this period were significantly higher compared to the other patients ($p=0.012$). There were no relationships between RDW and any other parameters analyzed (**Table 2**).

When tumor localizations were evaluated, a significant difference was found between the RDW values of patients with right colon tumor ($n=67$, 35.64%) and patients with rectal tumor ($n=74$, 39.36%) ($p=0.004$). Since the number of patients with tumors in other localizations such as the transverse colon ($n=15$, 7.98%), descending colon ($n=16$, 8.51%), sigmoid colon and rectosigmoid region ($n=16$, 8.51%) was insufficient, reliable statistical evaluations could not be performed with respect to specific sites (**Figure 1a**, **Table 1**). However, when tumor localizations were grouped, the median RDW values of patients with tumors in the right or transverse colon were significantly higher than that of patients with tumors in the descending or sigmoid colon or the rectum ($p<0.001$) (**Figure 1b**).

In addition, the median RDW value of patients who died was significantly higher compared to those who survived ($p=0.001$) (**Figure 2**).

There were significant weak positive correlations between RDW and several continuous variables, including age ($r=0.233$, $p<0.001$), tumor size ($r=0.229$, $p=0.002$) and length of stay in the hospital ($r=0.167$, $p=0.022$). There were no significant correlations between RDW values and the number of lymph nodes or the number of metastatic lymph nodes (**Table 3**).

Mortality prediction success of the RDW was found to be statistically significant (AUC: 0.704, 95.0% CI: 0.615 - 0.793, $p<0.001$) (**Figure 3**). RDW had 75.7% sensitivity, 67.5% specificity, 69.1% accuracy, 36.4% positive predictive value and 91.9% negative predictive value to predict mortality for the cut-off point of 15.7 (equal or higher values predict mortality) (**Table 4**).

Table 1. Summary of patients and tumor characteristics and laboratory measurements

| | |
|-------------------------------------|-----------------------|
| Age | 66.28±11.71 |
| Gender | |
| Female | 70 (37.23%) |
| Male | 118 (62.77%) |
| Location | |
| Right colon | 67 (35.64%) |
| Transverse colon | 15 (7.98%) |
| Descending colon | 16 (8.51%) |
| Sigmoid colon & rectosigmoid region | 16 (8.51%) |
| Rectum | 74 (39.36%) |
| Pathological diagnosis | |
| Non-mucinous adenocarcinoma | 138 (73.40%) |
| Mucinous adenocarcinoma | 50 (26.60%) |
| Tumor size | 40 (27.5 - 60) |
| Number of lymph nodes | 23 (16 - 34.5) |
| Number of metastatic lymph nodes | 0 (0 - 1) |
| Differentiation | |
| Poor | 20 (10.64%) |
| Moderate | 144 (76.60%) |
| Well | 24 (12.77%) |
| Radial surgical margin positivity | 4 (2.13%) |
| Distal surgical margin positivity | 3 (1.60%) |
| Perineural invasion | 42 (22.34%) |
| Lymphovascular invasion | 66 (35.11%) |
| T stage | |
| T1 | 6 (3.19%) |
| T2 | 33 (17.55%) |
| T3 | 118 (62.77%) |
| T4 | 31 (16.49%) |
| N stage | |
| N0 | 117 (62.23%) |
| N1 | 48 (25.53%) |
| N2 | 23 (12.23%) |
| Stage | |
| Stage 1 | 31 (16.49%) |
| Stage 2 | 85 (45.21%) |
| Stage 3 | 72 (38.30%) |
| Liver metastasis | 1 (0.53%) |
| Type of surgery | |
| Laparoscopy | 33 (17.55%) |
| Open surgery | 155 (82.45%) |
| Operation | |
| Right hemicolectomy | 53 (28.19%) |
| Transverse hemicolectomy | 10 (5.32%) |
| Left hemicolectomy | 21 (11.17%) |
| Anterior resection | 24 (12.77%) |
| Low anterior resection | 62 (32.98%) |
| Abdominoperineal resection | 17 (9.04%) |
| Other | 1 (0.53%) |
| Ostomy | 76 (40.43%) |
| Hemoglobin | 12.32±2.12 |
| Hematocrit | 37.89±5.56 |
| White blood cell (x1000) | 7.34 (5.90 - 9.60) |
| Neutrophil (x1000) | 4.83 (3.91 - 6.71) |
| Lymphocyte (x1000) | 1.48 (1.05 - 2.01) |
| Platelet (x1000) | 279 (223 - 372) |
| MPV | 9.56±1.15 |
| RDW | 14.65 (13.30 - 17.55) |
| Length of stay in hospital, days | 6 (5 - 9) |
| Follow-up time, months | 21 (12.5 - 28) |
| Leakage | 7 (3.72%) |
| Infection | 30 (15.96%) |
| Recurrence | 12 (6.38%) |
| Mortality | 37 (19.68%) |
| Early mortality (≤30 days) | 7 (3.72%) |

Data are given as mean±standard deviation or median (1st quartile - 3rd quartile) for continuous variables according to normality of distribution and as frequency (percentage) for categorical variables

Table 2. Summary of RDW with regard to patients and tumor characteristics

| | Median (1st quartile-3rd quartile) | p |
|-------------------------------------------|------------------------------------------|--------|
| Gender | | 0.033 |
| Female | 15.5 (13.7 - 17.9) | |
| Male | 14.55 (13.2 - 17.2) | |
| Location | | <0.001 |
| Right colon & Transverse colon | 16.25 (14.0 - 19.1) | |
| Descending colon & Sigmoid colon & Rectum | 14.2 (13.3 - 16.6) | |
| Pathological diagnosis | | 0.149 |
| Non-mucinous adenocarcinoma | 14.9 (13.5 - 17.8) | |
| Mucinous adenocarcinoma | 14.35 (13.2 - 17.2) | |
| Differentiation | | 0.477 |
| Poor | 13.95 (13.1 - 17.4) | |
| Moderate | 14.65 (13.4 - 17.35) | |
| Well | 16.1 (13.5 - 17.65) | |
| Perineural invasion | | 0.504 |
| No | 14.65 (13.4 - 17.8) | |
| Yes | 14.65 (13.3 - 17.2) | |
| Lymphovascular invasion | | 0.211 |
| No | 14.9 (13.3 - 17.8) | |
| Yes | 14.4 (13.3 - 17.1) | |
| T stage | | 0.001 |
| T1 & T2 | 13.8 (13.2 - 15.2) | |
| T3 & T4 | 15.3 (13.5 - 18.1) | |
| N stage | | 0.586 |
| N0 | 14.8 (13.5 - 17.7) | |
| N1 | 14.85 (13.3 - 16.9) | |
| N2 | 14.3 (13.1 - 18.4) | |
| Stage | | 0.010 |
| Stage 1 | 13.9 (13.2 - 15.3) | |
| Stage 2 & 3 | 15.1 (13.5 - 17.9) | |
| Leakage | | 0.271 |
| No | 14.6 (13.3 - 17.2) | |
| Yes | 17.9 (13.2 - 19.4) | |
| Infection | | 0.263 |
| No | 15.1 (13.3 - 17.8) | |
| Yes | 14.35 (13.5 - 15.7) | |
| Recurrence | | 0.086 |
| No | 14.6 (13.3 - 17.2) | |
| Yes | 17.2 (15 - 18.75) | |
| Status | | <0.001 |
| Alive | 14.4 (13.3 - 17.2) | |
| Exitus | 17.1 (15.7 - 19.1) | |
| Early mortality (≤ 30 days) | | 0.012 |
| No | 14.6 (13.3 - 17.2) | |
| Yes | 18.6 (17.1 - 20.2) | |

Same letters denote the lack of statistically significant differences between groups

Table 3. Relationships between RDW and continuous variables

| | r | p |
|----------------------------------|--------|-------|
| Age | 0.233 | 0.001 |
| Tumor size | 0.229 | 0.002 |
| Number of lymph nodes | 0.048 | 0.516 |
| Number of metastatic lymph nodes | -0.059 | 0.420 |
| Length of stay in hospital | 0.167 | 0.022 |

r: Spearman correlation coefficient




**Figure 1a, 1b.** Relationships between RDW and tumor site**Figure 2.** Relationship between RDW and mortality**Figure 3.** ROC curve of the RDW to predict mortality

Table 4. Performance of the RDW to predict mortality

| | |
|---------------------------------------------------------------------------------------------------------------------|-----------------------|
| Cut-off | ≥15.7 |
| Sensitivity | 75.7% |
| Specificity | 67.5% |
| Accuracy | 69.1% |
| PPV | 36.4% |
| NPV | 91.9% |
| AUC (95.0% CI) | 0.704 (0.615 - 0.793) |
| P | <0.001 |
| PPV: Positive predictive value, NPV: Negative predictive value, AUC: Area under ROC curve, CI: Confidence intervals | |

DISCUSSION

According to the results we obtained, it was found that the RDW values showed significant differences with respect to gender, age, tumor localization, T stage, clinical stage, duration of post-operative hospitalization, tumor size, early death, and death during follow-up.

CRC is the third most common cancer in both men and women and the second leading cause of cancer-related death (2,9,10). For these reasons, early diagnosis, proper treatment and prognostic assessment of CRC are critical. Blood tests are of great importance for diagnosis, treatment and prognosis, and help clinicians in assessing patients. In addition, the fact that blood tests are easier and less costly supports the focus of interest in the search for new markers associated with the diagnosis, treatment and prognosis of CRC (11-14). RDW is an indicator of the heterogeneity of red blood cell volume and is used in the diagnosis and prognosis of several diseases like anemia, some cardiovascular and infectious diseases and some types of cancer including lung, stomach, esophageal, hepatocellular, breast cancers, and, in recent years, CRC (15-23). In some studies, it has been shown that the RDW level of patients with CRC is higher than that of controls (3,4,7,8,24). The underlying cause of the relationship between RDW and cancer is unknown (1,25), but several possible mechanisms have been considered. The first is the hypothesis that inflammation and oxidative stress around the tumor may increase RDW. The second is that the tumor may indirectly cause changes in erythropoiesis by causing malnutrition, which may increase RDW. Finally, it is also possible that iron deficiency anemia due to bleeding seen in patients with CRC may increase RDW (26-28). All these results show that high RDW may be an independent risk factor for CRC (13).

In some studies, it has been shown that high RDW values might be a negative predictors of survival in several types of malignancies including lung, gastric, esophageal, hepatocellular cancers and breast cancer (1,15,17-20,29). A similar relationship has been suggested to exist between elevated RDW and CRC (8,30). Prior studies have also reported that RDW can independently assess the prognosis of patients with colorectal cancer (13).

Pedrazzani et al. (1) have shown that CRC patients with high RDW have a lower 10-year overall survival compared to those with lower RDW. Zhang et al. (30) found high RDW to be associated with poorer overall and disease-free survival in their study of 625 patients with rectal cancer who underwent curative surgery without neoadjuvant therapy. Li et al. (13), in a retrospective analysis of 168 colorectal cancer patients, found a positive relationship between RDW values and both 3- and 5-year overall and disease free survival. Similarly, high RDW was found to be associated with worse overall survival by Kust et al. (7) in a retrospective study of 90 patients with CRC; however, this relationship was only present in subjects with stage II cancer. Several other studies have also shown similar results (1,4,31). In this study, we also showed that the preoperative mean RDW values of patients who died during postoperative follow-up were significantly higher than those who survived. Also, interestingly, we found that patients who died within the first 30 days after surgery had higher RDW values. Additionally, it was observed that patients with high RDW had longer hospital stay after surgery. This significant relationship between high RDW and CRC-related deaths may be due to chronic inflammation due to cancer, iron deficiency anemia due to chronic blood loss in CRC, folate deficiency, changes in erythropoiesis, dyslipidemia and other metabolic abnormalities (32-36).

Today, TNM stage is accepted as the most significant prognostic factor for CRC (3). Many researchers have shown that RDW was significantly associated with clinical stage, T stage, N stage, M stage and tumor size in subjects with CRC. For instance, Song et al. (32) found that RDW values were associated with TNM stage, pT stage, and pM stage, similar to the results put forth by Yang and colleagues (8). Importantly, they also found that the level of RDW was associated with tumor size. However, there was a difference between the two studies with regard to the relationship between pN stage and RDW level. While the study by Yang et al. (8) found a significant positive correlation between RDW and pN stage, the study by Song et al. (32) did not. Moreover, Yang et al. (8) showed that RDW values in stage 3 and 4 CRC were higher compared to stage 1 and 2, similar to our results. In another research, RDW values were found to be associated with clinical stage, and T status, but not N or M status (4). Consistent with the results by Yang et al. (8), RDW values of CRC patients at the T3 and T4 stages in our study were found to be significantly higher than those with disease stages T1 and T2. We found similar results with regard to comparisons based on clinical staging. That is, the RDW levels of stage 1 patients were lower compared to patients with stage 2 or 3 disease. Likewise, we found that, as the tumor size increases, the RDW value also increases. Taking into

account these studies and our findings, it appears that increased tumor burden in CRC patients is associated with RDW elevation. Despite the fact that there are various studies showing the aforementioned relationship, the underlying causes for said relationship is not known exactly, but the increase in inflammatory activity around the tumor is likely a primary factor.

The relationship between the site of the CRC tumor and RDW has also been an interesting subject. In a study, RDW level was found to be significantly higher in right sided CRC tumors than left sided CRC tumors, similar to the present study (37). We also found higher RDW in patients with CRC tumors localized in the right or transverse colon compared to those with tumors in the descending colon, sigmoid colon or rectum. This interesting association may be a consequence of iron deficiency anemia. Right colon tumors are known to have a greater frequency of demonstrating bleeding and associated symptoms. As a result, anemia is a relatively more common symptom in tumors of the right colon compared to other regions of the colon (38).

Additionally, significant positive correlations between age and RDW levels have been reported previously (1,34,39), and we found supportive results in the current study. The relationship between gender and RDW is still unclear. Some studies have shown that the RDW is slightly higher in females (40), while others have found no significant association between RDW and gender. In our study, we also found that the RDW values of females were significantly higher than that of males; however, current data is not sufficient to draw conclusions regarding this matter.

Although our study showed significant relationships between RDW and various CRC characteristics that were largely consistent with previous studies, it has several limitations that must be noted. First, this is a single center and retrospective cohort study and has relatively few patients. Additionally, a control group was not included in this study, and therefore, comparisons with data from healthy patients were not possible. These may have led to various types of bias. Second, the number of patients in several sub-group analyses could have limited statistical reliability, and therefore, comparisons based on parameters such as tumor localization, pathological diagnosis, differentiation, T stage and N stage should be cautiously evaluated. Considering the presence of various studies showing some degree of relationship between elevated RDW and CRC prognosis, it appears that there is a need for further prospective, long-term multicenter studies with a larger number of patients to accurately assess the diagnostic and/or prognostic value of RDW in patients with CRC.

CONCLUSION

Both our study and similar studies have shown that CRC patients with high RDW levels have shorter postoperative survival or greater likelihood of death. Furthermore, elevated RDW seems to be associated with greater tumor size and more advanced clinical and TNM stages. All these relationships indicate a positive correlation between RDW values and the severity of CRC, and suggest that RDW may have a potential function as a diagnostic or prognostic marker in patients with CRC. For instance, it will not be surprising to suspect higher tumor burden in subjects with relatively elevated RDW –which could potentially be used to make decisions on surgical approach. However, in order for RDW to be accepted as a molecular marker associated with prognosis and survival in CRC, more comprehensive studies which can perform longer-term follow-up are needed.

ETHICAL DECLARATIONS

Ethics Committee Approval: The protocol of this study was approved by the Non-Interventional Clinical Researches Ethics Committee of Eskişehir Osmangazi University (Date:15.06.2021, Decision No: 09).

Informed Consent: Because the study was designed retrospectively, no written informed consent form was obtained from patients.

Referee Evaluation Process: Externally peer-reviewed.

Conflict of Interest Statement: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

Author Contributions: All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

1. Pedrazzani C, Tripepi M, Turri G, et al. Prognostic value of red cell distribution width (RDW) in colorectal cancer. Results from a single-center cohort on 591 patients. *Sci Rep* 2020; 10: 1072.
2. Simon K. Colorectal cancer development and advances in screening. *Clin Interv Aging* 2016; 11: 967-76.
3. Song Y, Huang Z, Kang Y, et al. Clinical Usefulness and prognostic value of red cell distribution width in colorectal cancer. *Biomed Res Int* 2018; 2018: 9858943.
4. Shi C, Xie M, Li L, Li K, Hu BL. The association and diagnostic value of red blood cell distribution width in colorectal cancer. *Medicine (Baltimore)* 2019; 98: e15560.
5. Jandial A, Kumar S, Bhalla A, Sharma N, Varma N, Varma S. Elevated red cell distribution width as a prognostic marker in severe sepsis: a prospective observational study. *Indian J Crit Care Med* 2017; 21: 552-62.
6. Ay S, Eryilmaz MA, Aksoy N, Okus A, Unlu Y, Sevinc B. Is early detection of colon cancer possible with red blood cell distribution width? *Asian Pac J Cancer Prev* 2015; 16: 753-6.

7. Kust D, Lucijanic M, Urch K, et al. Clinical and prognostic significance of anisocytosis measured as a red cell distribution width in patients with colorectal cancer. *QJM* 2017; 110: 361-7.
8. Yang D, Quan W, Wu J, et al. The value of red blood cell distribution width in diagnosis of patients with colorectal cancer. *Clin Chim Acta* 2018; 479: 98-102.
9. Siegel R, Jemal A. Colorectal cancer facts & Figures, 2011–2013. Atlanta, GA: American Cancer Society 2011.
10. Group UCSW. United States cancer statistics: 1999–2014 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2017.
11. Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. *Sci Rep* 2018; 8: 2732.
12. Nikolaou S, Qiu S, Fiorentino F, Rasheed S, Tekkis P, Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. *Tech Coloproctol* 2018; 22: 481-98.
13. Li Y, Xing C, Wei M, et al. Combining red blood cell distribution width (RDW-CV) and CEA predict poor prognosis for survival outcomes in colorectal cancer. *J Cancer* 2019; 10: 1162-70.
14. Zhao JX, Liu LR, Yang XY, Liu F, Zhang ZG. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. *Oncotarget* 2017; 8: 67918-32.
15. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. *Best Pract Res Clin Gastroenterol* 2010; 24: 381-96.
16. Koma Y, Onishi A, Matsuoka H, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. *PLoS One* 2013; 8: e80240.
17. Zhao T, Cui L, Li A. The significance of RDW in patients with hepatocellular carcinoma after radical resection. *Cancer Biomark* 2016; 16: 507-12.
18. Yazici P, Demir U, Bozkurt E, Isil GR, Mihmanli M. The role of red cell distribution width in the prognosis of patients with gastric cancer. *Cancer Biomark* 2017; 18: 19-25.
19. Chen GP, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer. *Mediators Inflamm* 2015; 2015: 854670.
20. Huang DP, Ma RM, Xiang YQ. Utility of red cell distribution width as a prognostic factor in young breast cancer patients. *Medicine (Baltimore)* 2016; 95: e3430.
21. Di Somma S, Magrini L, Travaglino F, et al. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. *Clin Chem Lab Med* 2013; 51: 1167-75.
22. Mahmood NA, Mathew J, Kang B, Debari VA, Khan MA. Broadening of the red blood cell distribution width is associated with increased severity of illness in patients with sepsis. *Int J Crit Illn Inj Sci* 2014; 4: 278-82.
23. Sargento L, Simões AV, Longo S, Lousada N, Palma Dos Reis R. Red blood cell distribution width is a survival predictor beyond anemia and Nt-ProBNP in stable optimally medicated heart failure with reduced ejection fraction outpatients. *Clin Hemorheol Microcirc* 2017; 65: 185-94.
24. Spell DW, Jones DV, Jr., Harper WF, David Bessman J. The value of a complete blood count in predicting cancer of the colon. *Cancer Detect Prev* 2004; 28: 37-42.
25. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 2004; 53: 1137-44.
26. Dogan M, Kucuk U, Uz O. Red blood cell distribution width is worthwhile when interpreted with other inflammatory markers. *J Geriatr Cardiol* 2015; 12: 457-8.
27. Ephrem G. Red blood cell distribution width should indeed be assessed with other inflammatory markers in daily clinical practice. *Cardiology* 2013; 124: 61.
28. De Gonzalo-Calvo D, De Luxán-Delgado B, Rodríguez-González S, et al. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. *Cytokine* 2012; 58: 193-8.
29. Goyal H, Hu ZD. Prognostic value of red blood cell distribution width in hepatocellular carcinoma. *Ann Transl Med* 2017; 5: 271.
30. Zhang X, Wu Q, Hu T, Gu C, Bi L, Wang Z. Elevated red blood cell distribution width contributes to poor prognosis in patients undergoing resection for nonmetastatic rectal cancer. *Medicine (Baltimore)* 2018; 97: e9641.
31. Wang PF, Song SY, Guo H, Wang TJ, Liu N, Yan CX. Prognostic role of pretreatment red blood cell distribution width in patients with cancer: A meta-analysis of 49 studies. *J Cancer* 2019; 10: 4305-17.
32. Song CS, Park DI, Yoon MY, et al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. *Dig Dis Sci* 2012; 57: 1033-8.
33. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014; 370: 1298-306.
34. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. *Crit Rev Clin Lab Sci* 2015; 52: 86-105.
35. Lippi G, Sanchis-Gomar F, Danese E, Montagnana M. Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients. *Kardiol Pol* 2013; 71: 931-6.
36. Sharma R, Agrawal V, editors. The relationship between red blood cell distribution width (RDW CV) and C reactive protein (CRP) with the clinical outcomes in non-ST elevation myocardial infarction and unstable angina pectoris: a 6 months follow up study. *International Cardiovascular Forum Journal*; 2015.
37. Bilgin B, Sendur MaN, Hizal M, et al. Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization. *J Cancer Res Ther* 2019; 15: 54-60.
38. Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL, Napolitano LM. Preoperative anemia in colon cancer: assessment of risk factors. *Am Surg* 2002; 68: 582-7.
39. Alis R, Fuster O, Rivera L, Romagnoli M, Vaya A. Influence of age and gender on red blood cell distribution width. *Clin Chem Lab Med* 2015; 53: e25-8.
40. Lippi G, Salvagno GL, Guidi GC. Red blood cell distribution width is significantly associated with aging and gender. *Clin Chem Lab Med* 2014; 52: e197-9.